Core Viewpoint - The company is focusing on expanding its market presence in the fields of infectious diseases and chronic disease management, leveraging policy benefits to promote key products like glycosylated hemoglobin testing and respiratory multiplex testing products [2][3]. Group 1: Financial Performance - As of January 27, 2026, the company's stock closed at 24.72 yuan, down 3.29%, with a turnover rate of 13.46%, trading volume of 579,400 lots, and a transaction value of 1.397 billion yuan [1]. Group 2: Product Development and Market Strategy - The company is actively working on the domestic market launch of its respiratory multiplex testing products, which cover common respiratory pathogens and are designed for rapid screening of infectious diseases [2]. - The company has successfully launched the first domestic MSI testing kit based on fluorescent PCR melting curve method, addressing existing pain points in MSI testing and aiming to enhance the efficiency and quality of cancer patient diagnosis and treatment [3]. - The company is committed to maintaining a balance between R&D investment and cash flow management, focusing on high-output and high-barrier technology areas to drive operational quality [3]. Group 3: International Expansion and Local Operations - The company is establishing subsidiaries in Russia and the Philippines to promote localized operations, although specific progress on construction, registration, production plans, and initial sales targets has not been detailed [4][5]. - The company aims to become a globally influential IVD enterprise, with a multi-dimensional development strategy that includes increasing overseas revenue and AI-related income [5]. Group 4: Market Penetration and Channel Strategy - The company plans to leverage its advantages in the POCT field to enhance penetration in grassroots medical institutions and regional health centers, aligning with policies encouraging community healthcare [6][7]. - The company is exploring partnerships with chain pharmacies to expand its retail presence and is considering strategies for product differentiation across various channels [6][7]. Group 5: Future Outlook and Key Performance Indicators - The company is focused on measuring the success of its transformation into a global IVD solution provider through key quantitative indicators, including the proportion of overseas revenue and AI-related income [5].

Group 1 - The Nipah virus outbreak in India has led to increased attention on related concept stocks, with several companies responding urgently to the situation [1] - Companies such as Capbio and Daan Gene have reported significant stock price increases, with Capbio rising by 20% and Daan Gene by 9.99% as of January 27 [2] - Various A-share listed companies are disclosing their technology and product layouts related to Nipah virus testing, including Wanfu Bio and Shengxiang Bio, which have developed specific testing kits [3][4] Group 2 - Capbio has developed a Nipah virus nucleic acid testing kit using fluorescence PCR technology, providing essential support for global quarantine and disease control monitoring [4] - Wanfu Bio has launched different product forms of the Nipah virus nucleic acid testing kit, compatible with its molecular POCT platform and other PCR systems [3] - Some companies, such as Hualan Biological and others, have clarified that they do not have any business related to Nipah virus vaccines or products [5][6]

Group 1 - The Nipah virus outbreak in India has raised concerns, particularly in West Bengal, but its impact on China is considered minimal as no cases have been reported in the country [1] - The market has shown increased interest in stocks related to virus prevention and diagnostics, with companies like Capbio and Da'an Gene experiencing significant stock price increases [1] - The Nipah virus has a transmission period of 3 to 14 days, with initial symptoms resembling influenza, making early detection crucial for effective intervention [1] Group 2 - Several A-share listed companies have announced their developments in Nipah virus detection technologies, including Wanfu Bio and Shengxiang Bio, which have launched various testing kits [3][5] - Capbio has developed a Nipah virus nucleic acid detection kit, providing essential support for global quarantine and disease control monitoring [5] - Some companies, such as Hualan Vaccine and Yirui Bio, have clarified that they do not have any products related to Nipah virus prevention or treatment [5][6]

证券日报网讯1月27日，万孚生物（300482）在互动平台回答投资者提问时表示，公司国际部持续推动 海外业务的本地化运营，对公司业绩影响请参照公司未来定期报告。 ...

证券日报网讯 1月27日，万孚生物在互动平台回答投资者提问时表示，公司关于分子诊断最新的仪器为 全自动核酸提纯及实时荧光PCR分析系统WonNova1600（国械注准20253222465），WonNova1600突破 了传统PCR在空间、人力和效率上的多重边界，赋能医院更快、更准、更轻松应对各类挑战。 （编辑 丛可心） ...

Group 1 - The company, Wanfu Biology (300482), is actively focusing on channel expansion and will adjust its product promotion efforts based on market demand [1]

Group 1 - The recent outbreak of Nipah virus disease in West Bengal, India, has raised significant concern, with 5 confirmed cases reported, including healthcare workers, and nearly 100 individuals under home quarantine [1] - The impact of the Nipah virus outbreak on China is relatively minor, with no cases reported in the country, although there is a risk of imported cases that necessitates enhanced preventive measures [1][2] - Nipah virus has been known for over 20 years, with its first outbreak occurring in Malaysia in 1998, and it primarily affects South Asia and Southeast Asia [1][2] Group 2 - The Nipah virus primarily damages the central nervous system (90%) and respiratory system (62%), with a high fatality rate ranging from 40% to 75% [2] - Experts indicate that the Nipah virus has a low basic reproduction number (R₀) compared to influenza or COVID-19, and there have been no reports of large-scale airborne transmission [4] - Current antiviral treatments for Nipah virus are limited, with no approved drugs or vaccines available, although Ribavirin may be effective for treating Nipah virus encephalitis [4][5] Group 3 - Recent research has shown that VV116 has antiviral activity against Nipah virus in vitro and can improve survival rates in mouse models, indicating potential for treatment [4][5] - Several companies have reported possessing Nipah virus testing technology or products, but they have not yet achieved significant revenue from these offerings [6] - The most common testing method for Nipah virus is nucleic acid testing, and public health departments are equipped to handle such testing, which is deemed sufficient for current needs [6]

Group 1 - The Nipah virus outbreak in West Bengal, India has confirmed 5 cases with nearly 100 people under observation, prompting neighboring countries like Thailand and Nepal to enhance health screening for travelers from India [1] - The World Health Organization (WHO) classifies the Nipah virus as a high-priority regional threat due to its high mortality rate of 40%-70% and the absence of approved vaccines or treatments [4][11] - The research team from Wuhan Institute of Virology has published findings indicating that the oral nucleoside drug VV116 shows significant antiviral activity against the Nipah virus, providing new hope for treatment [2][8] Group 2 - VV116, developed by Wangshan Wangshui and Junshi Biosciences, has shown potential against various RNA viruses, including the Nipah virus, and has been approved for COVID-19 treatment in China and Uzbekistan [7][8] - Following the announcement of VV116's efficacy against the Nipah virus, shares of Wangshan Wangshui surged by 10.9%, reaching a new high since its listing in November 2025 [4][5] - The market response to the Nipah virus outbreak has led to significant stock price increases for several companies involved in diagnostic testing, with companies like Kaipu Biological and Da'an Gene reporting substantial gains [12][13]

Group 1 - Capbio experienced a 20% limit-up increase, indicating strong market performance [1] - Zhifei Biological and Wanfu Biological both saw increases exceeding 10%, reflecting positive investor sentiment [1] - Zhijiang Biological and Hualan Vaccine previously reached limit-up, showcasing significant market interest [1] Group 2 - Companies such as CanSino, Shuoshi Biological, and Kehua Biological also reported notable gains, indicating a broader trend in the sector [1]

| 证券代码：300482 | 证券简称：万孚生物 | 公告编号：2025-010 | | --- | --- | --- | | 债券代码：123064 | 债券简称：万孚转债 | | 广州万孚生物技术股份有限公司 关于债券持有人可转债持有比例变动达 10%的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告。 1 广州万孚生物技术股份有限公司 一、可转换公司债券基本概况 经中国证券监督管理委员会"证监许可[2020]1830 号"文同意注册的批复， 公司于 2020 年 9 月 1 日向不特定对象发行了 600 万张可转换公司债券，每张面 值 100 元，发行总额 6.00 亿元。经深交所同意，公司 6.00 亿元可转换公司债券 于 2020 年 9 月 23 日起在深交所挂牌交易，债券简称"万孚转债"，债券代码 "123064"。 二、本次债券持有人持有可转债变动情况 近日，公司收到深圳市优美利投资管理有限公司（以下简称"优美利投资"） 的告知函，其管理的证券投资基金于 2025 年 12 月 12 日至 2026 年 1 月 26 日期 间 ...